基本信息来源于合作网站,原文需代理用户跳转至来源网站获取       
摘要:
BACKGROUND Ameloblastomas are common benign epithelial odontogenic neoplasms that present an aggressive and unpredictable behavior that may modify treatment strategies.Different signaling pathways that participate in the progression of these tumors have been identified.B-raf proto-oncogene serine/threonine kinase(BRAF)is a protein involved in the behavior of ameloblastomas,and it is related to many cell mechanisms.BRAF gene mutations have been identified in ameloblastomas,of which the BRAF V600E(valine substituted by glutamic acid at amino acid 600)mutation has been the most common and can be present concomitantly with other mutations that may be involved in its behavior.Targeted therapies have been used as an alternative in the case of resistance or contraindications to conventional treatments.AIM To document the presence of BRAF V600E and additional mutations,their behavior,and targeted therapies in these tumors.METHODS An electronic literature search was conducted according to PRISMA guidelines in PubMed/MEDLINE,Cochrane,EMBASE,and SpringerLink using the terms“ameloblastomas”,“BRAF V600E”,“additional mutations”,and“targeted therapies”.Ameloblastomas were classified according to WHO guidelines.Inclusion criteria were articles in English,published not more than 10 years ago,and studies with laboratory works related to BRAF V600E.Articles were evaluated by two independent reviewers and retrieved for full-text evaluation.The EBLIP Critical Appraisal Checklist was used to evaluate the quality of the eligible studies.Descriptive statistical analysis was performed.RESULTS Two independent reviewers,with a substantial concordance indicated by a kappa coefficient of k=0.76,evaluated a total of 19 articles that were included in this study.The analysis registered 521 conventional ameloblastomas(AM),81 unicystic ameloblastomas(UA),13 ameloblastic carcinomas(AC),three metastatic ameloblastomas(MA),and six peripheral ameloblastomas(PA),of which the histopathological type,anatomic location,laboratory tests,exp
推荐文章
黑色素瘤中癌基因B-RafV600E对B-Raf/ERK/Mps1负反馈抵抗作用的机制
黑色素瘤
B-Raf/MEK/ERK通路
Mps1
负反馈回路
B-RafV600E
AKT
人RAF1-RAS结合域蛋白的纯化及功能验证
人RAF1-RBD蛋白
原核表达
纯化
HRAS
蛋白相互作用
基于ARMS法检测BRAF V600E突变在甲状腺乳头状癌中的临床价值
甲状腺肿瘤
诊断
突变
扩增阻滞突变系统
BRAF基因
分化型甲状腺癌中BRAF V600E突变分析
甲状腺肿瘤
分化型甲状腺癌
甲状腺乳头状癌
BRAF V600E突变
组织学亚型
内容分析
关键词云
关键词热度
相关文献总数  
(/次)
(/年)
文献信息
篇名 Current concepts in ameloblastoma-targeted therapies in B-raf proto-oncogene serine/threonine kinase V600E mutation: Systematic review
来源期刊 世界临床肿瘤学杂志(英文版) 学科 医学
关键词 AMELOBLASTOMA B-RAF PROTO-ONCOGENE serine/threonine KINASE B-RAF protooncogene serine/threonine KINASE V600E Additional mutations Targeted therapies
年,卷(期) 2020,(1) 所属期刊栏目
研究方向 页码范围 31-42
页数 12页 分类号 R73
字数 语种
DOI
五维指标
传播情况
(/次)
(/年)
引文网络
引文网络
二级参考文献  (0)
共引文献  (0)
参考文献  (0)
节点文献
引证文献  (0)
同被引文献  (0)
二级引证文献  (0)
2020(0)
  • 参考文献(0)
  • 二级参考文献(0)
  • 引证文献(0)
  • 二级引证文献(0)
研究主题发展历程
节点文献
AMELOBLASTOMA
B-RAF
PROTO-ONCOGENE
serine/threonine
KINASE
B-RAF
protooncogene
serine/threonine
KINASE
V600E
Additional
mutations
Targeted
therapies
研究起点
研究来源
研究分支
研究去脉
引文网络交叉学科
相关学者/机构
期刊影响力
世界临床肿瘤学杂志:英文版
不定期
2218-4333
北京市朝阳区东四环中路62号楼远洋国际中
出版文献量(篇)
44
总下载数(次)
0
总被引数(次)
0
论文1v1指导